PHILIPS NV |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.44 USD | +5.38% |
|
-0.32% | +13.48% |
| 06:01pm | European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading | MT |
| May. 07 | PHILIPS : Jefferies remains negative, but raises its target | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 120.29 and 21.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.48% | 23.66B | - | ||
| +8.52% | 219B | B | ||
| +7.96% | 185B | B- | ||
| +14.42% | 135B | B- | ||
| +27.58% | 107B | A- | ||
| +14.22% | 51.28B | B+ | ||
| +4.48% | 51.01B | B+ | ||
| +3.91% | 41.85B | A | ||
| +6.48% | 37.02B | - | ||
| +25.05% | 31.27B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PHIA Stock
- PHG Stock
- Ratings Philips NV